Showing 81-90 of 3189 results for "".
- Doxycycline and Minocycline Show Benefit in OLP Gingival Lesionshttps://practicaldermatology.com/news/doxycycline-and-minocycline-show-benefit-in-olp-gingival-lesions/2485468/A retrospective analysis suggests doxycycline and minocycline may offer an effective systemic option for patients with inflammatory oral lichen planus (OLP) involving the gingiva who fail to respond to topical agents. Study res
- Low-Dose Minocycline Superior in Treating Inflammatory Rosaceahttps://practicaldermatology.com/news/low-dose-minocycline-dfd-29-superior-in-treating-inflammatory-rosacea/2485398/New data presented at 2026 Winter Clinical Hawaii showed DFD-29, a modified low-dose oral minocycline 40 mg, significantly outperformed both placebo and doxycycline 40 mg in the treatment of inflammatory lesions in patients with moderate-to-severe rosacea.
- Acne Incidence Higher with Higher-Dose LNG-IUS, Meta-Analysis Findshttps://practicaldermatology.com/news/acne-incidence-higher-with-higher-dose-lng-ius-meta-analysis-finds/2485045/A new systematic review and meta-analysis shows the incidence of acne among users of the levonorgestrel-releasing intrauterine system (LNG-IUS), identifying both dosage and age as influential factors. The review included nine ra
- Vixarelimab Shows Dose-Dependent Efficacy in Prurigo Nodularis Phase 2b Trialhttps://practicaldermatology.com/news/vixarelimab-shows-dose-dependent-efficacy-in-prurigo-nodularis-phase-2b-trial/2484982/Vixarelimab demonstrated dose-dependent improvements in itch severity and skin lesion clearance in patients with moderate to severe prurigo nodularis (PN), according to new results from a phase 2b randomized clinical trial. Res
- Lebrikizumab Maintains Efficacy With Reduced Dosing Intervalhttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-with-reduced-dosing-interval/2484255/Long-term data from a 32-week extension of the ADjoin trial suggest that lebrikizumab, an IL-13 inhibitor approved for once-monthly dosing, may maintain clinical efficacy in patients with moderate-to-severe atopic dermatitis (AD) even when administered once every 8
- Biosimilar STEQEYMA Now Approved for All Ustekinumab Dosage Forms, Strengthshttps://practicaldermatology.com/news/Biosimilar-STEQEYMA-Now-Approved-All-Ustekinumab-Dosage-Forms-Strengths/2475172/The US Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, according to a press release from Celltrion, Inc. The additional pre
- Analysis: Methotrexate Does Not Enhance Adalimumab Outcomes in Psoriasishttps://practicaldermatology.com/news/methotrexate-does-not-enhance-adalimumab-outcomes-in-psoriasis/2475072/Concomitant methotrexate does not improve the effectiveness or persistence of adalimumab in plaque psoriasis, according to findings from a new study. Researchers investigating whether methotrexate enhances adalimumab’s durab
- Study: Ultralow-Dose Rituximab Effective in Pemphigushttps://practicaldermatology.com/news/study-ultralow-dose-rituximab-effective-in-pemphigus/2474602/A new 52-week clinical trial found that ultralow-dose rituximab (ULRTX) achieved comparable efficacy, safety, and B-cell depletion to standard and low-dose regimens in patients with moderate-to-severe pemphigus vulgaris (PV) and pemphigus foliaceus (PF).
- Biologic Costs for Plaque Psoriasis Doubled Since 2007, Study Findshttps://practicaldermatology.com/news/biologic-costs-for-plaque-psoriasis-double-since-2007-study-finds/2474189/A new analysis shows the average net annual cost of first-line biologic treatments for plaque psoriasis more than doubled between 2007 and 2021, rising from $21,236 to $47,125. The study researchers, publishing online in J
- Bempikibart Shows Durable Responses, Post-Dosing Cessation for Severe AAhttps://practicaldermatology.com/news/Bempikibart-Shows-Durable-Responses-Post-Dosing-Cessation-Severe-AA/2471651/A novel IL-7/TSLP bifunctional receptor agonist has shown long-term durable responses and post-dosing cessation for patients with severe or very severe alopecia areata, according to a presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, by Brett King,